Why Sequenom (SQNM) Stock Was Up Today

NEW YORK (TheStreet) -- Sequenom, Inc. (SQNM) shares finished trading Monday up 9.1% to $3.34 following news that the company gained pre-market FDA clearance for its IMPACT genotyping test.

The noninvasive prenatel test analyzes chromosonal material in cell free DNA for pregnant women at an increased risk for fetal chromosonal abnormalities.

The San Diego-based company formed a licencing agreement with Quest Diagnostics (DGX) -- expected to make the test available by the third quarter-- to expand patient access to the test.

Must ReadWarren Buffett's 25 Favorite Stocks 

SQNM Chart

SQNM data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Stocks Close Lower But Trim Losses With Late Rebound

Stocks Close Lower But Trim Losses With Late Rebound

China Set to 'Weaponize' Yuan to Fight Trump's Trade War: Report

China Set to 'Weaponize' Yuan to Fight Trump's Trade War: Report

Jim Cramer on Canopy Growth's New $4 Billion Stake From Constellation Brands

Jim Cramer on Canopy Growth's New $4 Billion Stake From Constellation Brands

Jim Cramer on the Market Selloff, Macy's, Constellation Brands and Canopy Growth

Jim Cramer on the Market Selloff, Macy's, Constellation Brands and Canopy Growth

Jim Cramer Breaks Down the Decline in Macy's Stock Even With a Strong Quarter

Jim Cramer Breaks Down the Decline in Macy's Stock Even With a Strong Quarter